Get the Stockscreener App
2.24
5.16%
0.11
Pre-market:
2.20
-0.04
-1.79%
Cerus Corp stock is traded at $2.24, with a volume of 3.33M.
It is up +5.16% in the last 24 hours and down -2.18% over the past month.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
See More
Previous Close:
$2.13
Open:
$2.18
24h Volume:
3.33M
Relative Volume:
2.22
Market Cap:
$430.28M
Revenue:
$199.19M
Net Income/Loss:
$-16.02M
P/E Ratio:
-26.45
EPS:
-0.0847
Net Cash Flow:
$168.00K
1W Performance:
-7.44%
1M Performance:
-2.18%
6M Performance:
+68.42%
1Y Performance:
+41.77%
1-Day Range:
$2.06
$2.30
1-Week Range:
$1.88
$2.68
52-Week Range:
$1.12
$2.955
Cerus Corp Stock (CERS) Company Profile
Name
Cerus Corp
Sector
Industry
Phone
(925) 288-6000
Address
1220 CONCORD AVENUE, CONCORD, CA
Compare CERS vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CERS
Cerus Corp
|
2.24 | 409.15M | 199.19M | -16.02M | 168.00K | -0.0847 |
|
ABT
Abbott Laboratories
|
113.10 | 197.42B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
381.89 | 147.18B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
95.60 | 124.16B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
72.21 | 109.58B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
85.22 | 49.49B | 6.07B | 1.06B | 1.34B | 1.8063 |
Cerus Corp Stock (CERS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-12-24 | Initiated | Craig Hallum | Buy |
| Jan-20-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-17-23 | Downgrade | Stephens | Overweight → Equal-Weight |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Jun-16-20 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-26-20 | Initiated | BTIG Research | Buy |
| Nov-13-19 | Upgrade | BTIG Research | Neutral → Buy |
| Aug-28-19 | Initiated | Stifel | Buy |
| Aug-23-19 | Resumed | Stephens | Overweight |
| Jan-05-18 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-08-17 | Resumed | BTIG Research | Neutral |
| Jul-07-16 | Resumed | Cantor Fitzgerald | Buy |
| Dec-17-15 | Downgrade | Wedbush | Outperform → Neutral |
| May-02-14 | Reiterated | MLV & Co | Buy |
| Apr-24-13 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-15-13 | Reiterated | MLV & Co | Buy |
| Apr-17-12 | Initiated | Cantor Fitzgerald | Buy |
| Feb-29-12 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Nov-10-11 | Reiterated | MLV & Co | Buy |
| Jun-03-11 | Initiated | Wedbush | Outperform |
| Mar-04-11 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-09-10 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Aug-26-09 | Upgrade | Avondale | Mkt Perform → Mkt Outperform |
View All
Cerus Corp Stock (CERS) Latest News
CERS Earnings History & Surprises | EPS & Revenue Results | CERUS CORP (NASDAQ:CERS) - ChartMill
Cerus Corporation (NASDAQ:CERS) Q4 2025 Earnings Call Transcript - Insider Monkey
Cerus (CERS) Revenue Growth Outpaces Market And Reinforces Bullish Margin Recovery Narrative - simplywall.st
Cerus at TD Cowen Conference: Strategic Growth in Blood Transfusion - Investing.com South Africa
$CERS stock is down 16% today. Here's what we see in our data. - Quiver Quantitative
MongoDB, Surgery Partners, Harrow And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Cerus Corp (CERS) Q4 2025 Earnings Call Highlights: Record Reven - GuruFocus
Cerus: Q4 Earnings Snapshot - theheraldreview.com
Cerus Corp reports results for the quarter ended December 31Earnings Summary - TradingView
Cerus Q4 Earnings Call Highlights - Yahoo Finance
Cerus Corp (NASDAQ:CERS) Reports Mixed Q4 2025 Results, Stock Falls on Revenue Miss - ChartMill
Cerus: Q4 Financial Results Overview - Bitget
Earnings call transcript: Cerus Corporation Q4 2025 exceeds revenue expectations - Investing.com
Cerus (NASDAQ:CERS) Posts Quarterly Earnings Results, Hits Expectations - MarketBeat
Cerus 10-K: Revenue $233.8M, product growth drives results - TradingView
Cerus (NASDAQ: CERS) outlines INTERCEPT blood system pipeline - Stock Titan
CERS Forecasts Growth in 2026 Product Revenue - GuruFocus
Cerus Corporation (CERS) Stock Rises on Q4 2025 Earnings - Quiver Quantitative
Cerus falls 7% after posting in-line Q4 earnings, revenue beat - Investing.com Canada
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Cerus Q4 Earnings Assessment - Benzinga
Cerus (Nasdaq: CERS) grows 2025 revenue 16% and reaffirms 2026 outlook - Stock Titan
CERSCerus Corporation Announces Full-Year and Fourth Quarter 2025 Financial Results - ADVFN Ltd
Cerus (CERS) Set to Release Q4 Earnings with Modest Revenue Grow - GuruFocus
CERS PE Ratio & Valuation, Is CERS Overvalued - Intellectia AI
Cerus (NASDAQ:CERS) Stock Price Crosses Above 200-Day Moving AverageShould You Sell? - MarketBeat
Earnings Preview For Cerus - Sahm
Live Cerus fireside chat set for TD Cowen health conference March 3 - Stock Titan
Cerus (NASDAQ:CERS) Shares Pass Above 200-Day Moving AverageShould You Sell? - MarketBeat
Cerus sets March 2 date for Q4 and full-year 2025 earnings call - Stock Titan
Cerus Corporation to Release Fourth Quarter and Full-Year 2025 Financial Results on March 2, 2026 - Yahoo Finance
Cerus (CERS) Projected to Post Quarterly Earnings on Thursday - Defense World
Will Cerus Corporation (CU2) stock announce special dividend2025 Key Lessons & Proven Capital Preservation Tips - mfd.ru
Market Wrap: Is VLGEAs ROE strong enoughQuarterly Trade Report & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Cerus (CERS) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Cerus (NASDAQ:CERS) Stock Passes Above Two Hundred Day Moving Average – Here’s Why - Defense World
Cerus (NASDAQ:CERS) Stock Passes Above Two Hundred Day Moving AverageHere's Why - MarketBeat
Cerus announces planned board transition as director departs - The Globe and Mail
Cerus director Timothy L. Moore to step down after 2026 annual meeting - Investing.com
New German trial tests safer platelets for cancer patients - stocktitan.net
DRK Blood Donation Service Baden-Württemberg – Hessen Starts INITIATE Study to Evaluate Pathogen-Inactivated Platelet Concentrates Treated with Cerus’ INTERCEPT™ Blood System in Routine Clinical Practice - Yahoo Finance
Sumitomo Mitsui Trust Group Inc. Lowers Stock Holdings in Cerus Corporation $CERS - MarketBeat
Is Cerus Corporation being accumulated by smart money2025 Volume Leaders & High Accuracy Investment Signals - baoquankhu1.vn
Cerus (NASDAQ:CERS) Sets New 52-Week HighWhat's Next? - MarketBeat
Analysts Offer Insights on Healthcare Companies: Cerus (CERS) and Kura Oncology (KURA) - The Globe and Mail
TD Cowen reiterates Buy rating on Cerus stock after strong Q4 results - Investing.com
CERS Projects Revenue Growth in 2026 - GuruFocus
Cerus (CERS) Reports Significant Global Expansion of INTERCEPT B - GuruFocus
Cerus (CERS) Reports Strong Revenue Growth Driven by INTERCEPT F - GuruFocus
Cerus expects 14% jump in 2025 topline, guides 2026 (CERS:NASDAQ) - Seeking Alpha
Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2025 Product Revenue and Provides Outlook - Yahoo Finance
Cerus Corp Stock (CERS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.27%
1.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):